Acute psychosis leads to increased QT variability in patients suffering from schizophrenia.

Bär K-J, Koschke M, Boettger MK, Berger S, Kabisch A, Sauer H, et al.. Acute psychosis leads to increased QT variability in patients suffering from schizophrenia. Schizophrenia Res. 2007;95(1-3):115-23. DOI: 10.1016/j.schres.2007.05.034. PubMed PMID: 17630259.

An open-label, pilot trial of adjunctive tocilizumab in schizophrenia.

Miller BJ, Dias JK, Lemos HP, Buckley PF. An open-label, pilot trial of adjunctive tocilizumab in schizophrenia. J Clin Psychiatry. 2016;77(2):275-6. DOI: 10.4088/JCP.15l09920. PubMed PMID: 26930525.

A pilot randomized clinical trial evaluating the impact of genetic counseling for serious mental illnesses.

Hippman C, Ringrose A, Inglis A, Cheek J, Albert AYK, Remick R, et al. A pilot randomized clinical trial evaluating the impact of genetic counseling for serious mental illnesses. J Clin Psychiatry. 2016;77(2):e190-8. DOI: 10.4088/JCP.14m09710. PubMed PMID: 26930535.

Assessing cognitive impairment in patients with schizophrenia.

Schulz SC, Murray A. Assessing cognitive impairment in patients with schizophrenia. J Clin Psychiatry. 2016;77 Suppl 2:3-7. DOI: 10.4088/JCP.14074su1c.01. PubMed PMID: 26919051.

Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia.

Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry. 2016;77 Suppl 2:8-11. DOI: 10.4088/JCP.14074su1c.02. PubMed PMID: 26919052.

Behavioral and emerging pharmacologic treatment options for cognitive impairment in schizophrenia.

Vinogradov S, Schulz SC. Behavioral and emerging pharmacologic treatment options for cognitive impairment in schizophrenia. J Clin Psychiatry. 2016;77 Suppl 2:12-6. DOI: 10.4088/JCP.14074su1c.03. PubMed PMID: 26919053.

Ditching our simplistic systems for categorising mental health problems.

Dudleston KE. Ditching our simplistic systems for categorising mental health problems. BMJ. 2016;352:i1044. DOI: 10.1136/bmj.i1044. PubMed PMID: 26905081.

Rebranding schizophrenia is unlikely to reduce stigma.

Hamilton I. Rebranding schizophrenia is unlikely to reduce stigma. BMJ. 2016;352:i1043. DOI: 10.1136/bmj.i1043. PubMed PMID: 26905294.

"Schizophrenia" is a useful concept.

Lawrie SM. "Schizophrenia" is a useful concept. BMJ. 2016;352:i1046. DOI: 10.1136/bmj.i1046. PubMed PMID: 26908463.

Schizophrenia: changing the name and broadening the concept is problematic.

Sommer IE, Carpenter WT. Schizophrenia: changing the name and broadening the concept is problematic. BMJ. 2016;352:i1080. DOI: 10.1136/bmj.i1080. PubMed PMID: 26908503.